Leadership Overview
Takeda Oncology has 5 executives leading key functions including operational strategy, medical affairs, global business management, and oncology unit leadership.
Driven by a commitment to patient-centric innovation, Takeda Oncology advances life-changing therapies through rigorous research and global development, aiming to transform the standard of care for cancer patients worldwide.
Driven by a commitment to patient-centric innovation, Takeda Oncology advances life-changing therapies through rigorous research and global development, aiming to transform the standard of care for cancer patients worldwide.
Leadership Roles at Takeda Oncology
Christophe Bianchi - President
Christophe Bianchi, the President at Takeda Oncology, directs the strategic vision and commercial expansion of the oncology business unit. Bianchi oversees the development of high-impact therapeutic portfolios, focusing on scaling operations to meet the needs of patients in international markets. The President manages the integration of research and commercial functions to ensure that Takeda Oncology delivers consistent value to the healthcare ecosystem. By fostering partnerships with global stakeholders, Christophe Bianchi drives the growth of the oncology pipeline. This leadership role involves navigating complex regulatory landscapes and market dynamics to secure the long-term success of the business unit. Through the strategic guidance of the President, the organization optimizes its market position and enhances its ability to provide specialized cancer care. Bianchi ensures that all commercial activities align with the core mission of advancing oncology medicine, ultimately supporting the delivery of life-saving treatments to diverse patient populations across the globe.
Rob Smith - President
Rob Smith, the President at Takeda Oncology, architects the organizational structure and operational framework required to sustain the company's leadership in the pharmaceutical industry. Smith focuses on internal efficiency and the optimization of supply chain logistics to ensure the reliable distribution of oncology therapies. The President manages the alignment of regional business units, ensuring that Takeda Oncology maintains a cohesive approach to market entry and product lifecycle management. By driving initiatives that improve operational agility, Rob Smith supports the rapid deployment of new cancer treatments. This leadership role involves collaborating with the executive team to refine business models and enhance competitive performance. Through the oversight of the President, the organization achieves sustainable growth and operational stability. Smith ensures that all internal functions support the overarching goal of providing high-quality oncology care, effectively managing the complexities of a global pharmaceutical business to benefit patients in every region.
Teresa Bitetti - Global President, Oncology Business Unit
Teresa Bitetti, the Global President, Oncology Business Unit at Takeda Oncology, directs the overarching strategy and commercial performance of the entire oncology portfolio. Bitetti oversees the global expansion of therapeutic offerings, ensuring that Takeda Oncology maintains a dominant presence in the competitive pharmaceutical landscape. The Global President, Oncology Business Unit manages the strategic direction of the business unit, coordinating with other C-suite leaders to align research, development, and commercial goals. By championing innovation and patient-centric solutions, Teresa Bitetti drives the long-term success of the organization. This leadership role involves setting the vision for global market penetration and ensuring that the business unit meets its financial and clinical objectives. Through the guidance of the Global President, Oncology Business Unit, the company continues to advance its mission of transforming cancer care. Bitetti ensures that all strategic decisions prioritize the needs of patients, fostering a culture of excellence and scientific advancement across all international operations.
Tawnee Friedrich - Chief Of Staff, GMAO
Tawnee Friedrich, the Chief Of Staff, GMAO at Takeda Oncology, directs the operational cadence and strategic alignment within the Global Medical Affairs Oncology division. Friedrich manages cross-functional workflows to ensure that medical insights translate into actionable development strategies for oncology therapies. By coordinating internal communications and resource allocation, the Chief Of Staff, GMAO optimizes the efficiency of global teams. This leadership role involves bridging the gap between clinical research and commercial execution to support the broader mission of Takeda Oncology. Through rigorous oversight of departmental initiatives, Tawnee Friedrich maintains high standards of operational excellence. The Chief Of Staff, GMAO facilitates collaboration across international regions, ensuring that medical strategies remain consistent with the overarching goals of the business unit. Ultimately, Friedrich drives the internal processes necessary to deliver advanced cancer treatments to patients across diverse global markets.
Rushi Potdar - Chief Medical Officer & Head of Global Medical Affairs, Global Oncology Business Unit (Gobu)
Rushi Potdar, the Chief Medical Officer & Head of Global Medical Affairs, Global Oncology Business Unit (Gobu) at Takeda Oncology, architects the clinical strategy and medical evidence generation for the entire oncology portfolio. Potdar oversees the scientific integrity of all therapeutic programs, ensuring that clinical data supports the development of innovative cancer treatments. The Chief Medical Officer & Head of Global Medical Affairs, Global Oncology Business Unit (Gobu) manages relationships with global health authorities and key opinion leaders to advance the medical mission. By integrating scientific rigor into commercial planning, Rushi Potdar ensures that Takeda Oncology remains at the forefront of pharmaceutical innovation. This role requires constant evaluation of clinical trial outcomes and medical trends to guide long-term research investments. Through the leadership of the Chief Medical Officer & Head of Global Medical Affairs, Global Oncology Business Unit (Gobu), the organization maintains a robust pipeline of therapies designed to address unmet patient needs on a global scale.
Explore Leadership Teams in Manufacturing
Novartis is a global pharmaceutical manufacturer headquartered in Switzerland, specializing in developing and producing innovative medications and healthcare solutions. The company focuses on research and development of treatments across multiple therapeutic areas to address various medical conditions and improve patient outcomes worldwide. Novartis maintains a significant presence in scientific research, with extensive operations spanning across Europe, North America, Asia, and other global regions.
Company Leadership WV
AA
IP
Telix Pharmaceuticals is a global, commercial-stage biopharmaceutical company headquartered in North Melbourne, Australia, publicly listed on the Australian Securities Exchange and Nasdaq under the ticker TLX. The company specializes in the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, commonly referred to as theranostics, which use molecularly targeted radiation to both image and treat cancer. Telix's pipeline is focused on urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma), and bone marrow conditioning. Its lead commercial product, Illuccix, is an approved PSMA-PET/CT imaging agent for prostate cancer with regulatory clearance from the FDA, Australia's TGA, and Health Canada.
Company Leadership KR
CB
DS
Morepen Laboratories is a leading pharmaceutical company specializing in Active Pharmaceutical Ingredients (APIs) and finished formulations. With a commitment to quality and innovation, the company offers a wide range of healthcare, grooming, and OTC products under trusted brands like Dr. Morepen and Gubb World, catering to over 100 million consumers. Morepen has a robust global presence, exporting to over 80 countries and holding certifications from regulatory authorities such as USFDA and WHO GMP. The company is dedicated to enhancing lives through its extensive research and development efforts and state-of-the-art manufacturing facilities.
Company Leadership VS
PM
TA
21st Century Vitamins operates as a globally recognized manufacturer and distributor of dietary supplements, positioned within the broader health and wellness industry. The company, through its parent entity 21st Century HealthCare, Inc., focuses on developing, producing, and delivering a wide range of vitamins, minerals, herbal supplements, and specialty nutritional products designed to support everyday health and well-being. With a history spanning more than three decades, the organization has established itself as a trusted and accessible brand in the consumer healthcare market. At its core, the company functions as both a manufacturer and a direct-to-consumer wellness provider. It produces an extensive portfolio of dietary supplements that cater to diverse health needs, including general nutrition, immune support, cardiovascular health, digestive wellness, sports nutrition, and beauty supplements. Its offerings range from traditional multivitamins and single-nutrient formulations to advanced blends such as amino acids, probiotics, and plant-based supplements. This breadth of product categories reflects the companys strategy of addressing a wide spectrum of consumer health requirements through scientifically formulated solutions.
Company Leadership SS
FC
KW
Frequently Asked Questions Regarding Takeda Oncology Top Executives and Leadership Team
